Ascendis Pharma A/S Stock News

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SLANG Worldwide

Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Tuesday, BidAskClub reports. Several other

The top-ranked sectors are healthcare, technology, consumer goods, and utilities.

Geode Capital Management LLC increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 0.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exc

Altium Wealth Management LLC acquired a new stake in Ascendis Pharma A/S (NASDAQ:ASND) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC

Ascendis Pharma A/S (NASDAQ:ASND) – Stock analysts at SVB Leerink decreased their Q1 2020 EPS estimates for Ascendis Pharma A/S in a research report issued to clients and investors on Monday, April

Ascendis Pharma A/S (NASDAQ:ASND) had its price target hoisted by equities research analysts at Cantor Fitzgerald from $185.00 to $201.00 in a research report issued on Monday, MarketBeat reports. The

Ascendis Pharma A/S (NASDAQ:ASND) had its target price hoisted by stock analysts at Stifel Nicolaus from $146.00 to $171.00 in a research report issued on Monday, The Fly reports. The brokerage curren

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective lifted by analysts at Oppenheimer from $199.00 to $219.00 in a report released on Monday, The Fly reports. The firm presently has an “outper

Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by stock analysts at JPMorgan Chase & Co. from $145.00 to $150.00 in a note issued to investors on Monday, The Fly reports. The firm prese

Biofrontera inks a new deal and announces earnings. Ascendis reports top line data from TransCon trial. Precigen will start a phase 2/3 trial in HPV.

The latest analyst coverage could presage a bad day for Ascendis Pharma A/S (NASDAQ:ASND), with the analysts making...

Market forces rained on the parade of Ascendis Pharma A/S (NASDAQ:ASND) shareholders today, when the analysts...

Bank of America Corp DE lowered its position in Ascendis Pharma A/S (NASDAQ:ASND) by 25.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exch

After Merrill Lynch and Canaccord Genuity gave Ascendis Pharma (NASDAQ: ASND) a Buy rating last month, the company received another Buy, this time from